alvelestat

all catalysts(0)

nothing on the calendar yet

News(2)

• Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset
  Mereo BioPharma’s asset, dubbed alvelestat, is set to enter Phase 3 development for AATD-LD in 2027.
  biospace · 5d ago
• Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
  Sentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.
  fiercebiotech · 6d ago